Product Description
Mechanisms of Action: SQS Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hypercholesterolemia|Type 2 Diabetes|Dyslipidemia|Hyperlipoproteinemia Type II
Phase 2: Hypercholesterolemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2008-006906-41 | P3 |
Completed |
Unknown |
2010-05-22 |
|
2007-001489-34 | P3 |
Terminated |
Hypercholesterolemia |
2009-06-01 |
|
TAK-475_306 | P3 |
Terminated |
Hypercholesterolemia |
2008-05-01 |
|
TAK-475_307 | P3 |
Terminated |
Hypercholesterolemia |
2008-04-01 |